<DOC>
	<DOC>NCT01922154</DOC>
	<brief_summary>To evaluate the effects of intravitreal ranibizumab (IVR) as adjunctive treatment for trabeculectomy with mitomycin C (TMC) in neovascular glaucoma (NVG).</brief_summary>
	<brief_title>Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma</brief_title>
	<detailed_description>This is a prospective study of 15 consecutive eyes from 14 patients (One patients had NVG in both eyes at presentation.) with NVG presented at the Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand between December 2008 and December 2009. Each eye received IVR (0.5 mg/0.05 ml) 1 week before TMC. Trabeculectomy was performed with fornix-based conjunctival flap method.</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Neovascular</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Consecutive patients with neovascular glaucoma Age more than 80 year old Provide written informed consent Uncooperated patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Angiogenesis inhibitors</keyword>
	<keyword>Neovascular</keyword>
	<keyword>Intraocular pressure</keyword>
	<keyword>Retinal Vein Occlusion</keyword>
	<keyword>Vascular Endothelial Growth Factor</keyword>
</DOC>